Abstract
Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients (SCAN): Awareness of specialized techniques and latest interventions
Journal of clinical oncology, Vol.38(15_suppl), pp.e16708-e16708
05/20/2020
DOI: 10.1200/JCO.2020.38.15_suppl.e16708
Abstract
e16708
Background: SCAN measured global readiness to provide diagnostics and treatments for NET patients in terms of awareness, availability, quality and affordability. This analysis focused on patient and healthcare professional (HCP) awareness of NET diagnostics and treatments. Methods: During Sept-Nov 2019, NET patients and HCPs completed an online survey (available in 14 languages). Results: There were 2795 respondents from 68 countries across 6 continents (2359 patients/carers; 436 HCPs). Primary NETs were most often gastroenteropancreatic NETs (GEP NET; 71% [1408/1983]), particularly small intestinal (35% [690/1983]) or pancreatic (20% [402/1983]). Biopsy was the most well-known diagnostic option in the overall NET patient group (82% [1917/2325]), the GEP NET patient subgroup (83% [1156/1395]) and HCPs (94% [411/435]), followed by CT (all patients: 81% [1874/2325]; GEP NET: 80% [1118/1395]; HCPs: 86% [376/435]). More HCPs were aware of specialized diagnostics, such as
68
Ga-DOTA PET CT (HCP 81% [353/435]) and chromogranin A (CgA; 79% [344/435]), than patients (all: 68% [1574/2325] & 62% [1451/2325], respectively; GEP NET: 69% [962/1395] & 67% [936/1395]). The vast majority of all patients (87% [1983/2275]), GEP NET patients (89% [1215/1363]) and HCPs (91% [392/431]) knew surgery was a treatment option. Somastatin analogues were recognised as a treatment option by 90% of HCPs (387/431), but only 75% of GEP NET patients (1019/1363) and 70% of all NET patients (1599/2275). Nearly a quarter of HCPs (22% [95/431]) and one-third of patients (all: 33% [755/2275]; GEP NET: 30% [409/1363]) had not heard of peptide receptor radionuclide therapy (PRRT). The majority of patients (all: 88% [2007/2273]; GEP NET: 89% [1213/1370]) and HCPs (93% [396/425]) were aware of conventional imaging, such as CT/MRI/ultrasound, being used for ongoing monitoring of NETs. Approximately a third of all NET patients and a quarter of HCPs were unware CgA (patients: 32% [723/2273]; HCPs: 22% [94/425]) or
68
Ga-DOTA PET CT (patients: 29% [670/2273]; HCPs: 24% [102/425]) were ongoing monitoring tools. Similarly, CgA and
68
Ga-DOTA PET CT were not recognized by 27% of GEP NET patients (364/1370 & 371/1370, respectively). Conclusions: Increased awareness of NET diagnostics and treatments, particularly newer, more specialized tools, amongst both HCPs and patients is required to ensure continued advancements and improvements in the global standard of care for NETs.
Details
- Title: Subtitle
- Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients (SCAN): Awareness of specialized techniques and latest interventions
- Creators
- Mark McDonnell - NET Patient Network, Dublin, IrelandDirk Van Genechten - VZW NET & Men Kanker Belgium, Kortrijk, BelgiumTeodora Kolarova - International Neuroendocrine Cancer Alliance, Boston, MADermot O'Toole - Trinity College DublinHarjit Singh - Prince Court Medical Centre 39, Jalan Kia Peng, Kuala Lumpur, MalaysiaJie Chen - The First Affiliated Hospital, Sun Yat-sen UniversityJames R. Howe - University of IowaSimron Singh - University of TorontoCatherine Bouvier - NET Patient Foundation, Leamington Spa, United KingdomChristine Rodien-Louw - APTED Association de Patients Porteurs de Tumeurs Endocrines Diverses, Lyon, FranceSimone Leyden - UnicornSugandha Dureja - Fortis Memorial Research Institute
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.38(15_suppl), pp.e16708-e16708
- DOI
- 10.1200/JCO.2020.38.15_suppl.e16708
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Grant note
- name: Ipsen and Isotopen Technologien Munchen
- Language
- English
- Date published
- 05/20/2020
- Academic Unit
- Surgery
- Record Identifier
- 9984322891802771
Metrics
9 Record Views